FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE; NOTICE OF MEETING; ESTABLISHMENT OF A PUBLIC DOCKET; REQUEST FOR COMMENTS-SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) 205422/S-012 FOR REXULTI (BREXPIPRAZOLE) TABLETS

WASHINGTON, June 17 -- Food and Drug Administration has issued a notice called: Psychopharmacologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Supplemental New Drug Application (sNDA) 205422/S-012 for REXULTI (brexpiprazole) Tablets.

The notice was published in the Federal Register on June 17 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Psychopharmacologic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be op...